Cartesian Therapeutics Inc. (RNAC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cartesian Therapeutics Inc. (RNAC) has a cash flow conversion efficiency ratio of 0.149x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.14 Million) by net assets ($-148.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View RNAC live share price for real-time trading data and today's change.
Cartesian Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Cartesian Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see RNAC company net worth for the company's overall valuation and market capitalisation.
Cartesian Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cartesian Therapeutics Inc. ranked by their cash flow conversion efficiency. Also see RNAC total assets for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suheung Capsul
KO:008490
|
0.017x |
|
Gia Lai Electricity JSC
VN:GEG
|
0.076x |
|
New World Resources Ltd
AU:NWC
|
-0.015x |
|
Robot Consulting Co., Ltd. ADS
NASDAQ:LAWR
|
N/A |
|
Answer Technology Co Ltd
TW:3528
|
-1.025x |
|
Akenerji Elektrik Uretim AS
IS:AKENR
|
0.044x |
|
Fasadgruppen Group AB
ST:FG
|
0.124x |
|
Forte Biosciences Inc
NASDAQ:FBRX
|
-0.166x |
Annual Cash Flow Conversion Efficiency for Cartesian Therapeutics Inc. (2014–2025)
The table below shows the annual cash flow conversion efficiency of Cartesian Therapeutics Inc. from 2014 to 2025. Review Cartesian Therapeutics Inc. (RNAC) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-126.24 Million | $-73.94 Million | 0.586x | -83.17% |
| 2024-12-31 | $-6.80 Million | $-23.67 Million | 3.480x | +2894.54% |
| 2023-12-31 | $-440.18 Million | $-51.16 Million | 0.116x | +134.48% |
| 2022-12-31 | $93.83 Million | $-31.63 Million | -0.337x | +87.43% |
| 2021-12-31 | $22.52 Million | $-60.38 Million | -2.681x | -38.40% |
| 2020-12-31 | $-18.01 Million | $34.88 Million | -1.937x | +68.37% |
| 2019-12-31 | $8.40 Million | $-51.44 Million | -6.125x | -156.10% |
| 2018-12-31 | $-5.42 Million | $-59.16 Million | 10.919x | +1187.25% |
| 2017-12-31 | $51.81 Million | $-52.04 Million | -1.004x | -180.41% |
| 2016-12-31 | $54.96 Million | $-19.68 Million | -0.358x | -285.74% |
| 2015-12-31 | $-116.49 Million | $-22.46 Million | 0.193x | +33.39% |
| 2014-12-31 | $-87.75 Million | $-12.69 Million | 0.145x | -- |
About Cartesian Therapeutics Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune disease… Read more